Decision-making in the management of adult classical Hodgkin’s lymphoma: determining the optimal treatment

References

• Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008;112:4384-99
   PubMed Web of Science ®Google Scholar
• Nikiforow S, Lacasce AS. Targeting Epstein-Barr virus-associated lymphomas. J Clin Oncol 2014;32:830-2
   PubMedGoogle Scholar
• Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 2009;4:3-10
   PubMed Web of Science ®Google Scholar
• Cheson B, Fisher R, Barrington S, et al. Recommendations for Initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma – the lugano classification. J Clin Oncol 2014. [Epub ahead of print]
   Google Scholar
• Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-54
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. international prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 1998;339:1506-14
   PubMed Web of Science ®Google Scholar
• Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol 2012;30:3383-8
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Mounier N, Andre M, et al. How to define intermediate stage in Hodgkin’s lymphoma? Eur J Haematol Suppl 2005(66):111-14
   PubMedGoogle Scholar
• Casasnovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin’s lymphoma: a study from the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007;25:1732-40
   PubMed Web of Science ®Google Scholar
• Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res 2013;19:6812-19
   PubMed Web of Science ®Google Scholar
• Sauer M, Plutschow A, Jachimowicz RD, et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol 2013;88:113-15
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 2013;121:3547-53
   PubMed Web of Science ®Google Scholar
• Scott DW, Chan FC, Hong F, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 2013;31:692-700
   PubMed Web of Science ®Google Scholar
• Hutchings M, Kostakoglu L, Zaucha JM, et al. In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma. J Clin Oncol 2014;32:2705-11
   PubMed Web of Science ®Google Scholar
• Cerci JJ, Trindade E, Pracchia LF, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin’s lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol 2010;28:1415-21
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791-9
   PubMed Web of Science ®Google Scholar
• Meignan M, Barrington S, Itti E, et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 2014;55:31-7
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014. [Epub ahead of print]
   Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-52
   PubMed Web of Science ®Google Scholar
• Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014;99:1107-13
   PubMed Web of Science ®Google Scholar
• Jones K, Vari F, Keane C, et al. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res 2013;19:731-42
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012;366:399-408
   PubMed Web of Science ®Google Scholar
• Thomas J, Ferme C, Noordijk E. Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma. Haematologica 2007;92:C010
   Google Scholar
• Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica 2010;95:494-500
   PubMed Web of Science ®Google Scholar
• Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014;32:1188-94
   PubMed Web of Science ®Google Scholar
• Radford J, Barrington S, Counsell N. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD: Results of the UK NCRI RAPID Trial. Blood 2012; 547
   PubMedGoogle Scholar
• Bonadonna G, Viviani S, Bonfante V, et al. Survival in Hodgkin’s disease patients--report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005;41:998-1006
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 1998;16:3810-21
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003;348:2386-95
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-54
   PubMed Web of Science ®Google Scholar
• Wongso D, Fuchs M, Plutschow A, et al. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the German Hodgkin study group. J Clin Oncol 2013;31:2819-24
   PubMed Web of Science ®Google Scholar
• Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013;14:943-52
   PubMed Web of Science ®Google Scholar
• Mounier N, Brice P, Bologna S, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles >/= 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014;25:1622-8
   PubMed Web of Science ®Google Scholar
• Carde P, Karrasch M, Fortpied C, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles 5> 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. American Society of Clinical Oncology 48th annual meeting, June, 1-5 2012. J Clin Oncol 2012;30; Abstr 8002
   Google Scholar
• Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-11
   PubMed Web of Science ®Google Scholar
• Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203-12
   PubMed Web of Science ®Google Scholar
• Montanari F, Diefenbach C. Relapsed Hodgkin Lymphoma: Management Strategies. Curr Hematol Malig Rep 2014;9(3):284-93
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012;119:1665-70
   PubMed Web of Science ®Google Scholar
• Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol 2010;28:5074-80
   PubMed Web of Science ®Google Scholar
• Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica 2012;97:1073-9
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008;26:5980-7
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310-17
   PubMed Web of Science ®Google Scholar
• Satwani P, Jin Z, Martin PL, et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:2183-9
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 2013;14:1348-56
   PubMed Web of Science ®Google Scholar
• Borchmann P, Eichenauer D, Pluetschow A, et al. Targeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II study. Haematologica 2014; ESH2014:S1292
   Google Scholar
• Boll B, Plutschow A, Fuchs M. German Hodgkin study group phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older Hodgkin lymphoma patients. Blood 2013;122:3054
   PubMed Web of Science ®Google Scholar
• Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol 2003;14:1562-9
   PubMedGoogle Scholar
• Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002;100:1984-8
   PubMed Web of Science ®Google Scholar
• Spina M, Rossi G, Antinori A, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV). Ann Oncol 2008;19:152; Abst 227
   Google Scholar
• Tanaka PY, Pessoa VPJr, Pracchia LF, et al. Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clin Lymphoma Myeloma 2007;7:364-8
   PubMedGoogle Scholar
• Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica 2007;92:191-8
   PubMedGoogle Scholar
• Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 2012;30:4111-16
   PubMed Web of Science ®Google Scholar
• Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol 2012;30:4117-23
   PubMed Web of Science ®Google Scholar
• Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012;119:692-5
   PubMed Web of Science ®Google Scholar
• Jarrett RF, Stark GL, White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 2005;106:2444-51
   PubMed Web of Science ®Google Scholar
• Landgren O, Algernon C, Axdorph U, et al. Hodgkin’s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003;88:438-44
   PubMed Web of Science ®Google Scholar
• Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013;31:1522-9
   PubMed Web of Science ®Google Scholar
• Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of Adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 2013;161:76-86
   PubMed Web of Science ®Google Scholar
• Gopal AK, Bartlett NL, Forero-Torres A, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma 2014. [Epub ahead of print]
   Google Scholar